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Significance: Long-term opioid use is associated with serious adverse events such 
as major trauma, addiction and overdose. The risk increases with higher opioid 
doses. Opioid prescribing should be reviewed before long-term use becomes 
established, and periodically thereafter to assess on-going effectiveness. 
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Risk of adverse events in patients prescribed long-term opioids: a cohort 
study in the UK Clinical Practice Research Datalink 
Abstract  
Background: Long-term opioid prescribing for musculoskeletal pain is controversial 
due to uncertainty regarding effectiveness and safety. This study examined the risks 
of a range of adverse events in a large cohort of patients prescribed long-term 
opioids using the UK Clinical Practice Research Datalink.  
Methods: Patients with musculoskeletal conditions starting a new long-term opioid 
episode (defined as ≥3 opioid prescriptions within 90 days) between 2002-2012 were 
included. Primary outcomes: major trauma and intentional overdose (any). 
Secondary outcomes: addiction (any), falls, accidental poisoning, attempted 
suicide/self-harm, gastrointestinal pathology and bleeding, and iron deficiency 
anaemia. ‘Control’ outcomes (unrelated to opioid use): incident eczema and 
psoriasis.  
Results: 98,140 new long-term opioids users (median age 61, 41% male) were 
followed for (median) 3.4 years.  Major trauma risk increased from 285 per 10,000 
person-years without long-term opioids to 369/10,000 for a long-term opioid episode 
(<20mg MED), 382/10,000 (20-50mg MED), and 424/10,000 (≥50mg MED). 
Adjusted hazard ratios were 1.09 (95% CI, 1.04, 1.14 for <20mg MED vs. not being 
in an episode of long-term prescribing), 1.24 (95% CI, 1.16, 1.32: 20-50mg MED) 
and 1.34 (95% CI, 1.20, 1.50: ≥50mg MED). Significant dose-dependent increases in 
the risk of overdose (any type), addiction, falls, accidental poisoning, gastrointestinal 
pathology, and iron-deficiency anaemia were also found.   
Conclusions: Patients prescribed long-term opioids are vulnerable to dose-
dependent serious adverse events. Opioid prescribing should be reviewed before 
long-term use becomes established, and periodically thereafter to ensure that 
patients are not being exposed to increased risk of harm, which is not balanced by 
therapeutic benefit.  
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Introduction 
Internationally, the use of prescribed opioid analgesics has increased substantially 
(Manchikanti et al., 2010; Zin et al., 2014; Bedson et al., 2016; Foy et al., 2016; 
Farias et al., 2017). Most opioid prescribing is for non-cancer pain and painful 
chronic musculoskeletal conditions account for two-thirds of long-term opioid 
prescribing (Ray et al., 2016). In UK primary care, 20% of adults consult with a 
musculoskeletal problem annually (Jordan et al., 2010). There was a 41% increase 
in patients with musculoskeletal pain prescribed opioids long-term (≥90 days) in the 
UK between 2002-2011. The proportion of these patients who were prescribed 
stronger, long-acting opioids rose from 4% to 23% between 2002-2013 (Bedson et 
al., 2016).  
Long-term opioid prescribing for musculoskeletal pain is controversial due to 
uncertainty regarding effectiveness and safety. Evidence for the long-term 
effectiveness of opioids from randomised placebo-controlled trials is lacking (Chou et 
al., 2015). A recent trial with 12 months follow-up found opioids were no more 
effective than non-opioid analgesics for chronic back pain and osteoarthritis (Krebs 
et al., 2017). However, limited evidence from open-label studies (Hauser et al., 
2015), combined with clinical experience and expert consensus, suggests some 
patients may benefit from opioids in a multifaceted pain management strategy 
(O'Brien et al., 2017).  
A Cochrane review reported significantly increased risks of a range of adverse 
events (including constipation, nausea, pruritus, dizziness, and drowsiness) with 
medium and long-term opioid use in chronic non-cancer pain (Els et al., 2017). 
Additionally, there was a paucity of follow-up data beyond 13 weeks and a lack of 
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important adverse events reporting, including overdose and addiction, and on their 
association with opioid dose.  United States (US) observational studies report 
associations between long-term opioid use and serious adverse events including 
bone fractures and overdose (Dunn et al., 2009; Saunders et al., 2010). Solomon 
investigated adverse events in opioid users in the USA between 1996-2005 and 
found that some, including fractures and all-cause mortality were potentially related 
to the opioid agent (Solomon et al., 2010).  A US study reported increased risk of all-
cause mortality during the first 180 days of therapy in patients prescribed opioids 
versus anticonvulsants and low-dose tricyclic antidepressants for chronic pain (Ray 
et al., 2016).  However, since these findings are restricted to subgroups of patients 
within the US healthcare system, their generalisability is uncertain.   
We aimed to address the limitations of existing evidence by investigating a broad 
spectrum of adverse events potentially associated with prescribed long-term opioids 
in a large UK primary care electronic heath record database, and to determine how 
any increased risks varied by opioid dose prescribed.  
One potential limitation of using observational data to investigate the risks of long-
term opioids is confounding by indication. To reduce the risk of confounding we have 
set our study within a population of patients with painful musculoskeletal conditions 
and included only patients who have ever been prescribed opioids long-term. Our 
assumption is that these were all patients for whom their GP had considered that 
opioids were a potentially appropriate analgesic and not contraindicated for long-
term use. We compared adverse events during episodes of long-term prescribing to 
adverse events during time periods where these patients were not prescribed long-
term opioids, adjusting for important covariates and including ‘control’ outcomes.  
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Methods 
Database  
This was a cohort study performed in the Clinical Practice Research Datalink 
(CPRD), an anonymised database of routinely recorded information from UK general 
practices. The population included in CPRD is representative of the UK population 
on age, gender and ethnicity, and validation studies generally show high levels of 
positive predictive values of diagnosis codes (Herrett et al., 2010; Herrett et al., 
2015). CPRD comprises information from over 20 million patients registered in more 
than 650 primary care practices spread throughout the UK (Williams et al., 2012; 
Tate et al., 2014). In the UK, the vast majority of the population are registered with a 
general practice, and it is here that 90% of all National Health Service (NHS) 
contacts occur (Gregory, 2009). Practices included in our analysis (n = 350, all from 
England) were required to have linked Office for National Statistics (ONS, for 
mortality information), Hospital Episode Statistics (HES), and Index of Multiple 
Deprivation (IMD, neighbourhood deprivation) data (Department for Communities 
and Local Government, 2010). Practices with and without linkage have been shown 
to be similar in respect of demographic data, years of follow-up, and prescribing 
(Gallagher et al., 2011).  
Cohort identification 
Cohort participants were those aged 18 years and over, starting a new long-term 
opioid episode at the time of a recorded non-inflammatory, potentially painful 
musculoskeletal condition between 2002 and 2012, as described previously (Bedson 
et al., 2016). Patients were included if a visit for a musculoskeletal condition 
occurred within a period starting 14 days before the initial opioid prescription, and up 
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to 90 days following it. This timeframe was chosen as it generated a temporal 
association between the musculoskeletal problem and the prescription, such that any 
painful musculoskeletal problem occurring within that time frame would potentially be 
affected by the opioid.  
Musculoskeletal conditions were chosen because they are a common reason for 
patients consulting in primary care, are associated with chronic pain in the majority of 
cases (Woolf et al., 2004) and represent the commonest causes of chronic non-
cancer pain (Breivik et al., 2006). Regular opioid use is more common in this group 
(Hudson et al., 2008) and chronic non-cancer pain accounts for the majority of the 
escalation in strong opioid prescribing (Zin et al., 2014).  
Musculoskeletal conditions were identified using previously defined Read codes 
taken from Chapters 1 (History and symptoms), N (Musculoskeletal), R (Symptoms), 
and S (Injury) (Jordan et al., 2010). Read codes are a hierarchical coded thesaurus 
of clinical terms used for recording morbidity in UK primary care (NHS Digital, 2018). 
The codes used in the current study are available at 
www.keele.ac.uk/mrr/morbiditydefinitions/ . Each participant was also required to 
have at least 12 months of records in the CPRD database before the initial opioid 
prescription, and have no record of cancer diagnosis prior to the initial opioid 
prescription and up to 6 months after the initial prescription.   
Long-term opioid use 
Opioids were defined as analgesics used to relieve moderate to severe pain from 
sections 4.7.1 and 4.7.2 of the British National Formulary (BNF) (BNF, 2017). The 
start of an episode of opioid prescribing was defined as the date an opioid 
prescription was issued for a patient who had not received an opioid prescription 
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within the previous 6 months. Long-term opioid prescribing was defined as the issue 
of at least 2 further opioid prescriptions within the 90-day period following the date 
the new opioid prescription was issued (i.e. at least 3 opioid prescriptions in total 
within 90 days). An episode of long-term opioid prescribing ended if a period of 6 
months elapsed without an opioid prescription. This definition is based on a 
classification of long-term opioid use that has been employed in previous studies 
(Von Korff et al., 2008; Dunn et al., 2010). The end date of a long-term opioid 
episode was defined as the date 28 days following the issue of the last opioid 
prescription, in keeping with local health authority guidance setting a maximum of 28 
days supply of medication per prescription (Dowd, 2011). An individual patient may 
therefore have had multiple episodes of long-term opioid prescribing over the study 
period. 
Average daily dose 
Daily morphine equivalent dose (MED) is an accepted method of assigning a 
standard value for the dose of the many different opioids based on tables of their 
relative potency compared to morphine. The MED for each opioid medication was 
obtained by using a conversion factor for morphine equivalence shown in table 1, 
and detailed morphine equivalence sources are available at 
https://www.keele.ac.uk/mrr/morbiditydefinitions/ . The MED for a single prescription 
was calculated by multiplying the quantity of medication prescribed by the 
conversion factor. With respect of long-acting opioid patches (e.g. buprenorphine, 
fentanyl), the total MED for the patch was calculated by firstly determining the 24-
hour MED using the appropriate conversion factor to determine the amount released 
per hour multiplying by 24, and then by the number of days the patch was prescribed 
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for use (e.g. 4 or 7 days). Total morphine equivalent dose (total MED) in a long-term 
opioid episode was calculated by adding the MEDs for each prescription dispensed 
during the episode. Average daily morphine equivalent dose (average daily MED) 
prescribed was the total MED for a long-term opioid episode divided by episode 
duration in days. In those participants, where an outcome of interest occurred within 
a long-term opioid episode, average MED was calculated only for the period before 
that outcome occurred, in order to minimise the influence from a potential prescribing 
change due to an outcome event.  
Table 1 here 
Average daily dose for each long-term opioid episode was grouped into 3 categories 
(< 20mg MED; ≥ 20 & < 50mg MED; ≥ 50mg MED) adapted from a previous study 
(Dunn et al., 2010).  
Follow-up 
Cohort participants were followed up from the date 90 days after the initial opioid 
prescription in their first long-term opioid episode until the study end date (10th 
January 2012) or the date the patient no longer contributed data (due to leaving the 
practice, the practice leaving CPRD, or patient death), whichever occurred earlier. 
Outcome measures 
As primary outcomes we examined two adverse events with some previous evidence 
of an association with long-term opioid use in studies within selected healthcare 
populations in the US: namely major trauma (Saunders et al., 2010) and intentional 
overdose (opioid or other) (Dunn et al., 2009)  
Risk of adverse events in long-term opioid users 
9 
 
We defined major trauma as a bone fracture, joint dislocation, ligament or tendon 
rupture, or head trauma (including subdural haemorrhage). Read code examples of 
opioid overdose included ‘self-poisoning with an opioid’, and non-opioid overdose 
‘self-poisoning with a hypnotic’. It was not possible to determine if the codes used 
related to fatal or non-fatal overdoses.  
Secondary outcomes were attempted suicide/self-harm (excluding overdose), 
incident addiction (opioids), incident addiction (other type), falls, accidental 
poisoning, newly diagnosed gastrointestinal pathology (inflammatory or erosive, e.g. 
‘peptic ulcer’), gastrointestinal bleeding (gastric and non-gastric bleeding), and new 
diagnosis of iron deficiency anaemia (potentially occurring because of 
gastrointestinal bleeding). Accidental poisoning was coded per se, since all Read 
codes used to identify this type of outcome specifically state ‘accidental’ e.g. 
accidental poisoning by other tranquillisers (Code T83yz). All other self-poisonings or 
overdoses were then classified as intentional, since CPRD GPs are trained to use 
appropriate codes for the problem being documented, and where self-poisoning was 
‘accidental’, this would be labelled as such, leaving other codes inherently as 
intentional. This list includes adverse events where limited evidence of an 
association with long-term opioid use currently exists (Els et al., 2017), and where 
recognised side effects of opioids such as delayed gastrointestinal motility, 
confusion, dependence, drowsiness, dysphoria, postural hypotension, vertigo and 
visual disturbances, make an association feasible (BNF, 2017). Additionally, 
abdominal pain is a reported adverse effect from using the opioid codeine phosphate 
(BNF, 2017), and reports of anaemia have been recorded by the US FDA Adverse 
Events Recording System in users of opioids such as codeine (eHealthMe, 2017). 
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We therefore included gastrointestinal pathologies which can cause both abdominal 
pain and anaemia to investigate any association with opioid use.  
We also included two dermatological control outcomes, new diagnosis of eczema or 
psoriasis, that theoretically should have no relationship with long-term prescribed 
opioids. These act as ‘negative controls’ to identify possible sources of bias (e.g. due 
to unmeasured confounding) (Lipsitch et al., 2010, Arnold et al., 2016). Our 
hypothesis was that failure to identify an association of long-term opioid prescribing 
with these control outcomes would increase confidence that any associations found 
for the primary and secondary outcomes are less likely to be due to possible sources 
of bias. 
Outcomes of interest were the first recording of these adverse events within the 
follow-up period. Outcomes were analysed separately so an individual patient could 
have multiple different adverse events. All potential adverse events were identified 
through Read Codes in CPRD and Read Codes mapped to ICD-10 codes in the 
linked HES dataset, or where relevant through the linked ONS dataset for events 
ending in mortality. All relevant adverse event codes (available from 
https://www.keele.ac.uk/mrr/morbiditydefinitions/ ) appropriate for the analysis were 
identified through a consensus exercise by two academic primary care physicians 
(JB and RAH), experienced in identifying database codes. An incident event or new 
diagnosis was defined as a record made during the follow-up period with no such 
record during the 15 months prior to start of follow-up (365 days prior to initial opioid 
prescription to 90 days after).  
Covariates 
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Possible confounding covariates were identified. Prior occurrence of adverse events, 
except for those where the outcome was defined as an incident event or new 
diagnosis, were identified in the 15-month period prior to start of follow-up. 
Smoking and alcohol information were classified as ever, never or missing based on 
data prior to start of follow-up date. The missing category was included to maximise 
numbers in analysis. BMI value used was the record at the closest date before the 
start of follow-up, and was grouped into <25 kg/m2, ≥25 kg/m2 (overweight) or 
missing. 
Geographical region was grouped as London, South of England, Midlands and East 
of England, and North of England. Deprivation level, based on the Index of Multiple 
Deprivation 2010 [Department for Communities and Local Government], was 
categorised based on quintile score (1 least, 5 most deprived). The deprivation 
measure is an ecological indicator based on area of residence, covering seven 
aspects of neighbourhood deprivation including income, employment, health 
deprivation and disability, education skills and training, barriers to housing and 
services, crime, and living environment. 
Depression has been linked to use of opioids in studies from the US (Scherrer et al., 
2013; Scherrer et al., 2015; Scherrer, et al., 2015a,). We identified prior recorded 
depression in the 15 months prior to start of follow-up.  
Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with an increased 
risk of gastrointestinal adverse events (Lanza et al., 2009), therefore co-prescribing 
of a NSAID was identified using prescription data for the 4 months prior to follow-up 
start (to ensure any potential clinical NSAID-related adverse events that might 
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manifest themselves for up to 90 days after finishing a prescription of NSAID, usually 
issued for 28 days, could be taken into account).  
The total number of prescriptions for drugs recorded under different BNF sections in 
the 15-month period prior to start of follow-up was used as a surrogate measure of 
the number of co-morbid conditions at baseline (Perkins et al., 2004). 
Statistical analysis 
The rate of each of the adverse events per 10,000 person-years at risk were 
determined during follow-up, stratified by whether or not they occurred during an 
episode of long-term opioid prescribing, and by average daily dose during a long-
term opioid episode. 
Patients were followed up from 90 days after their initial opioid prescription in their 
first long term episode. For subsequent new opioid prescribing episodes, the first 90 
days was used to determine long-term opioid prescribing status according to our 
definition of ≥3 prescriptions in the first 90 days and this 90-day period was therefore 
excluded from the analysis of adverse events. Patients with an adverse event in that 
90 days were censored at time of initial opioid prescription for that episode. 
Proportional-hazards modelling was used to compare the risk of adverse events 
occurring during episodes of long-term opioid prescribing with the risk of adverse 
events occurring during episodes when long-term opioids were not being prescribed. 
Long-term opioid prescribing and average daily dose were treated as time-
dependent exposures. Patients were categorised as either currently being in a long-
term opioid episode or not currently being prescribed opioids. In those within a long-
term episode, patients were further categorised based on average daily dose (< 
20mg MED; ≥ 20 & < 50mg MED; ≥ 50mg MED). Separate models were performed 
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for each adverse event and for each of the two exposures (long-term episode status 
and average daily dose). 
Cox regression was used to produce both unadjusted and adjusted hazard ratios 
(HRs) for each outcome separately, estimating the excess risk of each adverse 
event associated with long-term opioid prescribing. The validity of the proportional-
hazards assumption was tested using Schoenfeld residuals and deemed adequate 
for the exposure variables of long-term opioid prescribing and average daily dose. 
Age at baseline, gender, year of start of follow-up, ever smoking, ever alcohol 
drinking, overweight (BMI ≥25kg/m2), geographical region, deprivation level, prior 
recorded depression, co-prescribing of NSAID, and total number of co-morbid 
conditions were included as baseline covariates in the final model. For the outcomes 
of major trauma, falls, intentional overdose (opioids and non-opioids separately) and 
accidental poisoning, baseline previous events were also included in the final model. 
For the outcomes of incident gastrointestinal conditions and bleeding, iron deficiency 
anaemia, addiction (opioids and non-opioids separately), eczema and psoriasis, 
patients with a previous event in their records were excluded from the analysis. We 
further stratified analysis by gender. 
A sensitivity analysis excluded patients with missing data on covariates. Analysis 
used Stata14.1. 
Results 
98,140 patients were prescribed long-term opioids during the study period. The 
median age (at start of follow-up) was 61 years, and 41% were males. Baseline 
characteristics are given in Table 2. Patients were followed for a median of 3.4 years 
(IQR 1.6, 5.8). 
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Table 2 here 
106,818 long-term opioid episodes were identified during the study period. The 
median length of long-term opioid episodes was 237 days (IQR 103, 658). This may 
be an underestimate as it includes the 27.4% of episodes that were not completed 
by the end of follow-up.  Within long-term opioid episodes, the median average daily 
dose of opioid prescribed to patients was 12.3 mg MED (IQR 7.1, 20.3 mg MED) 
(Table 3).  
Table 3 here 
Increased risks for major trauma and overdose (of both non-opioids and opioids) 
were found during episodes of long-term opioid prescribing, compared to periods 
when long-term opioids were not prescribed. Furthermore, higher risks were 
associated with a higher average daily MED. For example, risk of major trauma 
increased from 285/10,000 person-years at risk in periods when long-term opioids 
were not prescribed to 369/10,000 (average daily dose of <20mg MED), 382/10,000 
(20-50mg MED) and 424/10,000 (≥50mg MED) in periods of long-term opioid 
prescribing. Adjusted hazard ratios for the increase in risk were 1.09 (95% CI, 1.04, 
1.14 compared to not being in an episode of long-term use; <20mg MED), 1.24 (95% 
CI, 1.16, 1.32; 20-50mg MED) and 1.34 (95% CI, 1.20, 1.50; ≥ 50mg MED) (Table 
4).  
Table 4 here 
Dose-response relationships (i.e. increased risk in periods of stronger long-term 
opioid prescribing) were also identified for the secondary outcomes of falls, iron 
deficiency anaemia, gastrointestinal events, addiction, and accidental poisoning. The 
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number of attempted suicide/self-harm events was small, with no statistically 
significant relationship with long-term opioids observed (Table 5).  
Table 5 here 
Prescriptions of long-term opioids were not associated with increased risks of 
eczema or psoriasis, regardless of average daily dose (Table 6). 
Table 6 here 
Adjusted risks of adverse events were similar between females and males 
(Supplementary Tables 1-4). 
Sensitivity analysis using complete case analysis gave very similar results. 
Discussion and conclusions  
This study of nearly 100,000 patients in UK primary care has shown a dose-
dependent increase in the risk of overdose and major trauma when patients were 
prescribed long-term opioids for chronic musculoskeletal pain. Intentional opioid 
overdose was nearly 4 times more likely in patients prescribed long-term opioids at 
the highest doses (≥50mg) compared to periods  when they were not receiving long-
term opioids, Similarly, patients prescribed the highest doses also had a 71% higher 
risk of intentional non-opioid overdose and a 34% higher major trauma risk, 
compared to time periods when they were not prescribed long-term opioids. Dose-
dependent increases in the risk of addiction, falls, accidental poisoning, incident 
gastrointestinal pathology, gastrointestinal bleeding, and iron deficiency anaemia 
with current long-term opioid, compared to periods of no long-term use were also 
identified.  
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The median average daily dose of prescribed opioids during long-term opioid 
episodes was 12.3mg (IQR 7.1, 20.3 mg MED). This is consistent with an earlier 
dosage study of opioid prescribing (Von Korff et al., 2008) and another indicating that 
95% of initially prescribed opioids in long-term episodes were for low dose short-
acting non-controlled opioids (Bedson et al., 2016).  
Our study findings are consistent with smaller long-term opioid use observational 
studies in the US which demonstrated dose-dependent, increases in the risk of bone 
fractures (Saunders et al., 2010), opioid overdose (Dunn et al., 2009) and addiction 
(Edlund et al., 2014). Our finding of a dose-dependent increased risk of falls seems 
consistent with the increased risk of major trauma identified. In contrast, one large 
prospective longitudinal study found no significant association of opioids with falls or 
fractures in an all-male cohort (Krebs et al., 2016). However, this discrepancy may 
relate to the absence of data on opioid dose or duration, thereby potentially reducing 
the study’s power to detect a dose-dependent association if most events occur at 
higher doses. Adverse events in opioids might be related to the preparation. One 
systematic review found that transdermal buprenorphine was less likely to be related 
to adverse effects than other opioids (Richardson et al., 2018), and Solomon found 
that fractures were less likely in those who were prescribed tramadol compared to 
hydrocodone (Solomon et al., 2010). However, since our study considers MED as 
the main variable, we are unable to examine this phenomenon and therefore 
potentially some outcomes may be related more to the type of opioid than the MED. 
A higher risk of erosive gastrointestinal pathology, gastrointestinal bleeding, and iron 
deficiency anaemia has not previously been identified in relation to long-term 
opioids. Opioids may impair oesophageal motility and delay gastric emptying, 
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potentially worsening gastroesophageal reflux (Ratuapli et al., 2015), however, its 
clinical relevance is uncertain. Opioids are used as an alternative to NSAIDs for 
patients at risk of peptic ulcers and we cannot rule out residual confounding. Long-
term use of paracetamol (>13 weeks) has been associated with gastrointestinal 
blood loss (Doherty et al., 2011), and a systematic review reported higher rates of 
upper gastrointestinal bleeding in paracetamol users (Roberts et al., 2016). 
Paracetamol is frequently used in combination with opioids. Potentially, long-term 
opioid prescribing increases the likelihood of regular, long-term paracetamol use and 
that this is the risk factor associated with increased risk of gastrointestinal events, 
rather than the use of opioids per se. Although the analysis adjusted for prescribed 
NSAIDs, it did not adjust for paracetamol which may be purchased over the counter.  
Further exploration of this phenomenon is needed. 
A Cochrane review highlighted the lack of reporting on several important adverse 
events, such as addiction and overdose, and recommended longer follow-up to 
detect adverse events which this study has now examined. (Els et al., 2017).  
Reproductive and sexual dysfunction in occurs in male long-term opioid users. No 
such association has been identified in females (Daniell, 2002; Smith and Elliott, 
2012; Katz and Mazer, 2009). Therefore, other gender related differences in adverse 
events might exist. No studies have examined this area (Els et al., 2017) and we did 
not identify any differences in the rates of adverse events between males and 
females either. Patients moved from long-term opioid use to periods of no use. This 
would be consistent with previous work examining the trajectories of pain which 
people experience. For example, in back pain, one of the commonest causes of 
chronic non-cancer pain, pain trajectories are very variable and depend to some 
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extent on the original presentation. Backpain sufferers can be grouped according to 
those with persistent severe pain, fluctuating pain, persistent mild pain and 
occasional pain. However, all groups vary around their mean pain trajectory (Dunn et 
al., 2017, Tamcan et al., Pain 2010) which would be consistent with our findings of 
patients moving from periods of long-term opioid use to no use. 
Key strengths of this study relate to the use of CPRD, allowing analysis of a large 
cohort of primary care patients linked to secondary care and mortality data. All 
prescribing is recorded electronically in UK primary care at the point of medication 
issue and there is automatic recording of repeat opioid prescriptions. The likelihood 
of missing opioid prescribing data in CPRD is therefore low. Another factor 
facilitating the collection of outcome data and which makes our results more 
generalisable is the fact that primary care physicians in CPRD practices were 
historically requested to ensure recording of a diagnostic code for any new problem 
or when a new treatment is given (Lawson et al., 1998). CPRD data is not limited to 
particular healthcare populations, for example it is not based on medical insurance 
schemes as many USA healthcare databases are, thereby making the results more 
generalisable. Additionally, this population was restricted to patients with painful 
musculoskeletal conditions who had all been prescribed long-term opioids. This 
reduces the likelihood of cofounding by indication.  
We adjusted for previous occurrence of the adverse events, except for outcomes 
defined as incident events (where patients with a previous event were excluded), 
and for potential confounders. Depression and overdose during the past year are 
strong predictors of overdose and suicide in patients taking long-term opioids (Oliva 
et al., 2017). By adjusting for depression and previous overdose, we have controlled 
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for important confounders in relation to our primary outcome of overdose and 
increased confidence in the study findings. However, we were unable to adjust for a 
previous history of substance misuse which may influence some outcomes. 
We also included ‘control’ outcomes (Lipsitch et al., 2010; Arnold et al., 2016) which 
hypothetically should not be associated with long-term opioid prescribing to detect 
potential bias. The absence of any dose-dependent increased risk of either control 
outcome (incident eczema or psoriasis) further increases our confidence in the study 
findings. 
Our study was observational and therefore the results should be viewed as 
associations, and not necessarily causal. Our study population is restricted to 
patients with painful musculoskeletal conditions and, whilst this reflects the majority 
of patients with chronic pain, it is possible the findings may not be generalisable to 
those prescribed long-term opioids for non-musculoskeletal chronic pain. However, 
despite chronic musculoskeletal pain representing a broad range of heterogenous 
conditions, in light of recent research, (Artus et al., 2017; Green et al., 2018) which 
has demonstrated strong evidence that prognosis and prognostic factors are similar 
across multiple pain sites, we have assumed that the relationship of long-term opioid 
use with adverse events is consistent across musculoskeletal conditions, but future 
research should assess this further. 
Our study uses opioid prescribing data from a healthcare database and cannot 
account for patients not taking the prescribed medication as directed. In addition, we 
were unable to adjust for the use of over-the-counter analgesics. Long-term opioid 
use for musculoskeletal conditions is highly likely to be by prescription and therefore 
captured within the CPRD data, given that low dose codeine (8-12mg maximum 
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pack size of 32 tablets for short-term use) is the only opioid available over the 
counter in the UK (Medicines and Healthcare Products Regulatory Agency, 2009). 
However, it is possible that over the counter paracetamol or NSAID use may be 
implicated in the finding of higher risk of erosive gastrointestinal events.  Additionally, 
though our definition of long-term opioid use is dependent on the use of three 
consecutive prescriptions for opioids within 90 days, we cannot be certain that 
patients used them consistently in that period, and that every prescription was 
intended to last more or less than a four-week period. Though GPs are advised to 
use at least 2 – 4 weeks of an opioid before changing or stopping (NICE, 2017), and 
that at least 28 days of medication should be given (Dowd, 2016), this might lead to 
some patients being erroneously classed as long-term users, though within the 
framework that GPs work, the vast majority are likely to have been classified 
correctly.  Ultimately, however, the issue of a prescription for an opioid does not 
necessarily mean a patient has taken the medication. Accordingly, we cannot be 
certain whether a patient has used their prescribed opioids or not, though the fact 
that repeat prescriptions for opioids are issued in each long-term case would suggest 
that patients are likely to be using them. Although we adjusted for prescribed NSAID 
use, we did not adjust for any other prescribed medications used for chronic pain or 
other medications that might have impacted mental health such as antidepressants 
or benzodiazepines. However, we did adjust for total number of prescribed 
medications as a surrogate marker for comorbidity, but no specific co-morbidities 
other than depression were investigated such as substance misuse or osteoporosis 
which may impact overdose and bone fractures. Polypharmacy and the use of other 
medications for pain will be reflected to some extent by that. However, we are unable 
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to account for the specific effects of other potentially sedating medications on 
adverse event outcomes.  
We did not include adverse events occurring during the first 90 days of opioid 
prescribing as outcomes due to the likelihood of these being related to patients being 
opioid naïve. This study aimed to look at adverse events associated with long-term 
opioid use, and events after 90 days are more likely to be specifically associated with 
long-term use. However, events within 90 days were either adjusted for, or for 
incident outcomes, patients with such events were excluded.  
This study has shown dose-dependent associations between prescribed long-term 
opioids and increased risks of a range of serious adverse events.  Whilst in absolute 
terms, the increased number of events may be relatively small, this must be viewed 
in the context of both the seriousness of the events and the long-term efficacy of 
opioids for chronic pain. Whilst some patients may benefit from moderate doses of 
opioids for chronic pain, many do not (Moore et al., 2013). However, they may 
continue to be prescribed opioids because of a perceived lack of other treatment 
options (Moore et al., 2013; Stannard, 2013). It seems self-evident that patients 
should not be exposed to increased risk of harm, when this is not balanced by 
therapeutic benefit (Stannard, 2013; Faculty of Pain Medicine, 2013). Our findings 
reinforce the message that doctors need to be vigilant when prescribing opioids for 
chronic pain, and to give due consideration to the dose prescribed and the 
appropriateness of continuing opioids long-term. These clinical decisions must be 
made on an individual patient basis, taking into account any benefits observed in 
terms of pain relief, the impact on functioning, side-effects and the potential risks of 
long-term use. Opioid prescribing should be reviewed before long-term use becomes 
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established, and periodically thereafter to assess on-going effectiveness. 
Unfortunately, the challenges facing UK Primary Care, including rising GP workload, 
present a major barrier to this becoming routine practice (Primary Care Workforce 
Commission, 2015). Further research is needed to develop and test strategies and 
interventions to reduce inappropriate opioid prescribing. Given that most long-term 
opioid prescribing occurs in primary care, it is recommended that future research 
focusses on the role of multidisciplinary primary care teams, including clinical 
pharmacists, in reviewing patients prescribed long-term opioids.   
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Supplementary Table 1. Risks of major trauma and overdose in musculoskeletal patients newly prescribed long-term opioids in 
males 
Adverse event Number of 
events 
Time at risk 
(person-years) 
Absolute risk 
(per 10,000 person-
years) 
Crude hazard ratio 
(95% CI) 
Adjusteda hazard 
ratio (95% CI) 
Major trauma      
Periods not on long-term opioids 2,296 96,708.6 237.4 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 1,480 46,622.5 317.4 1.20 (1.12, 1.28) 1.13 (1.06, 1.21) 
 Periods on long-term opioids (daily MED < 20mg) 976 32,219.7 302.9 1.12 (1.04, 1.21) 1.08 (1.0, 1.17) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 403 11,210.2 359.5 1.39 (1.25, 1.55) 1.29 (1.15, 1.43) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 101 3,192.6 316.4 1.25 (1.03, 1.53) 1.09 (0.89, 1.33) 
       
Overdose (non-opioids)      
Periods not on long-term opioids 189 103,155.5 18.3 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 153 48,983.0 31.2 1.39 (1.11, 1.74) 1.25 (1.0, 1.58) 
 Periods on long-term opioids (ADD < 20mg MED) 70 33,667.8 20.8 0.88 (0.66, 1.17) 0.92 (0.69, 1.23) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 58 11,938.3 48.6 2.24 (1.66, 3.02) 1.67 (1.23, 2.26) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 25 3,377.0 74.0 3.58 (2.35, 5.44) 1.95 (1.27, 2.98) 
       
Overdose (opioids)      
Periods not on long-term opioids 53 103,499.2 5.1 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 63 49,168.6 12.8 2.34 (1.60, 3.43) 2.40 (1.62, 3.57) 
 Periods on long-term opioids (ADD < 20mg MED) 30 33,733.5 8.9 1.56 (0.98, 2.49) 1.89 (1.17, 3.06) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 19 12,029.3 15.8 2.88 (1.70, 4.90) 2.43 (1.42, 4.18) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 14 3,405.8 41.1 7.66 (4.24, 13.9) 4.70 (2.56, 8.64) 
ADD, average daily dose; MED, morphine equivalent dose; a Adjusted for age, index year, geographical region, smoking and alcohol status, body mass index, deprivation, 
depression consultation, comorbidity, co-prescribing of non-steroidal anti-inflammatory drug, and for prior occurrence of adverse event. 
Supplementary Table 2. Risks of major trauma and overdose in musculoskeletal patients newly prescribed long-term opioids in 
females 
Adverse event Number of 
events 
Time at risk 
(person-years) 
Absolute risk 
(per 10,000 person-
years) 
Crude hazard ratio 
(95% CI) 
Adjusteda hazard 
ratio (95% CI) 
Major trauma      
Periods not on long-term opioids 4,158 129,431.8 321.3 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 3,107 75,482.6 411.6 1.20 (1.14, 1.26) 1.14 (1.08, 1.19) 
 Periods on long-term opioids (daily MED < 20mg) 2,174 53,103.6 409.4 1.18 (1.12, 1.25) 1.10 (1.04, 1.16) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 693 17,519.4 395.6 1.18 (1.08, 1.28) 1.19 (1.09, 1.29) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 240 4,859.6 493.9 1.48 (1.30, 1.69) 1.43 (1.26, 1.63) 
       
Overdose (non-opioids)      
Periods not on long-term opioids 289 140,800.6 20.5 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 254 80,887.4 31.4 1.28 (1.07, 1.52) 1.21 (1.0, 1.44) 
 Periods on long-term opioids (ADD < 20mg MED) 119 56,720.8 21.0 0.81 (0.65, 1.02) 0.91 (0.72, 1.14) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 100 18,814.8 53.1 2.25 (1.78, 2.83) 1.70 (1.34, 2.15) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 35 5,351.8 65.4 2.85 (2.0, 4.0) 1.54 (1.08, 2.21) 
       
Overdose (opioids)      
Periods not on long-term opioids 65 141,502.1 4.6 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 88 81,217.9 10.8 2.06 (1.47, 2.88) 2.18 (1.55, 3.06) 
 Periods on long-term opioids (ADD < 20mg MED) 37 56,876.2 6.5 1.17 (0.77, 1.78) 1.42 (0.92, 2.18) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 37 18,923.3 19.6 3.79 (2.52, 5.71) 3.24 (2.14, 4.91) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 14 5,418.3 25.8 5.15 (2.89, 9.21) 3.38 (1.88, 6.08) 
ADD, average daily dose; MED, morphine equivalent dose; a Adjusted for age, index year, geographical region, smoking and alcohol status, body mass index, deprivation, 
depression consultation, comorbidity, co-prescribing of non-steroidal anti-inflammatory drug, and for prior occurrence of adverse event. 
 
 
Supplementary Table 3. Risks of falls, iron deficiency anaemia, gastrointestinal pathology, addiction, accidental poisoning and 
attempted suicide/self-harm in musculoskeletal patients newly prescribed long-term opioids in males 
Adverse event Number of 
events 
Time at risk 
(person-
years) 
Absolute risk 
(per 10,000 person-
years) 
Crude hazard ratio 
(95% CI) 
Adjusteda hazard 
ratio (95% CI) 
Fallsb      
Periods not on long-term opioids 2,530 96,939.4 261.0 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 1,785 46,202.8 386.3 1.41 (1.33, 1.51) 1.28 (1.20, 1.36) 
 Periods on long-term opioids (ADD < 20mg MED) 1,216 31,882.6 381.4 1.38 (1.29, 1.49) 1.18 (1.10, 1.27) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 421 11,206.7 375.7 1.39 (1.25, 1.54) 1.41 (1.27, 1.57) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 148 3,113.5 475.3 1.78 (1.50, 2.10) 1.99 (1.68, 2.35) 
       
Incident iron deficiency anaemiac      
Periods not on long-term opioids 813 100,603.4 80.8 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 620 47,495.1 130.5 1.62 (1.45, 1.81) 1.42 (1.27, 1.59) 
 Periods on long-term opioids (ADD < 20mg MED) 390 32,686.4 119.3 1.47 (1.30, 1.67) 1.21 (1.06, 1.37) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 171 11,547.2 148.1 1.83 (1.55, 2.16) 1.83 (1.55, 2.17) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 59 3,261.6 180.9 2.24 (1.72, 2.92) 2.46 (1.88, 3.22) 
       
Incident gastrointestinal pathologyc      
Periods not on long-term opioids 1,051 99,000.0 106.2 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 714 46,745.2 152.7 1.40 (1.26, 1.54) 1.26 (1.14, 1.40) 
 Periods on long-term opioids (ADD < 20mg MED) 469 32,278.9 145.3 1.32 (1.18, 1.48) 1.17 (1.04, 1.32) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 168 11,324.0 148.4 1.36 (1.16, 1.61) 1.27 (1.08, 1.50) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 77 3,142.3 245.0 2.27 (1.80, 2.86) 2.12 (1.68, 2.69) 
       
Incident gastrointestinal bleedingc      
Periods not on long-term opioids 489 101,682.4 48.1 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 312 48,144.2 64.8 1.25 (1.08, 1.46) 1.11 (0.95, 1.29) 
 Periods on long-term opioids (ADD < 20mg MED) 202 33,083.3 61.1 1.16 (0.98, 1.38) 1.01 (0.85, 1.20) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 77 11,741.6 65.6 1.29 (1.01, 1.64) 1.18 (0.92, 1.50) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 33 3,319.3 99.4 1.99 (1.39, 2.83) 1.80 (1.26, 2.58) 
       
Incident addiction (non-opioids) c      
Periods not on long-term opioids 353 101,834.6 34.7 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 317 48,005.0 66.0 1.70 (1.45, 2.0) 1.59 (1.35, 1.87) 
 Periods on long-term opioids (ADD < 20mg MED) 161 33,192.4 48.5 1.21 (0.99, 1.47) 1.22 (1.0, 1.49) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 110 11,618.5 94.7 2.49 (2.0, 3.09) 2.03 (1.63, 2.52) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 46 3,194.1 144.0 3.88 (2.85, 5.28) 2.75 (2.01, 3.76) 
       
Incident addiction (opioids) c      
Periods not on long-term opioids 54 103,164.3 5.2 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 77 48,978.3 15.7 2.45 (1.70, 3.53) 2.63 (1.81, 3.84) 
 Periods on long-term opioids (ADD < 20mg MED) 18 33,698.3 5.3 0.76 (0.44, 1.31) 0.96 (0.55, 1.68) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 32 11,964.3 26.7 4.19 (2.68, 6.55) 3.47 (2.20, 5.45) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 27 3,315.8 81.4 13.44 (8.43, 21.44) 8.10 (5.01, 13.09) 
       
Accidental poisoningb      
Periods not on long-term opioids 21 103,622.2 2.0 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 17 49,225.0 3.5 1.77 (0.90, 3.48) 1.48 (0.74, 2.94) 
 Periods on long-term opioids (ADD < 20mg MED) 8 33,751.9 2.4 1.19 (0.50, 2.79) 1.01 (0.43, 2.41) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 6 12,044.9 5.0 2.46 (0.98, 6.19) 2.06 (0.81, 5.28) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 3 3,428.2 8.8 4.38 (1.30, 14.78) 3.21 (0.93, 11.13) 
       
Attempted suicide/self-harmb      
Periods not on long-term opioids 7 103,666.6 0.7 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 6 49,242.0 1.2 1.89 (0.61, 5.80) 1.72 (0.55, 5.43) 
 Periods on long-term opioids (ADD < 20mg MED) 3 33,758.9 0.9 1.36 (0.34, 5.46) 1.49 (0.36, 6.15) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 2 12,051.1 1.7 2.53 (0.52, 12.32) 1.88 (0.38, 9.39) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 1 3,432.0 2.9 4.43 (0.54, 36.17) 2.39 (0.27, 20.73) 
ADD, average daily dose; MED, morphine equivalent dose; aAdjusted for age, index year, geographical region, smoking and alcohol status, body mass index, deprivation, 
depression consultation, comorbidity, and co-prescribing of non-steroidal anti-inflammatory drug ; bAlso adjusted for prior occurrence of adverse event; cExcluded patients with 
previous record of event. 
 
 
 
 
 
 
 
 
 
Supplementary Table 4. Risks of falls, iron deficiency anaemia, gastrointestinal pathology, addiction, accidental poisoning and 
attempted suicide/self-harm in musculoskeletal patients newly prescribed long-term opioids in females 
Adverse event Number of 
events 
Time at risk 
(person-
years) 
Absolute risk 
(per 10,000 person-
years) 
Crude hazard ratio 
(95% CI) 
Adjusteda hazard 
ratio (95% CI) 
Fallsb      
Periods not on long-term opioids 5,656 124,594.3 454.0 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 4,722 72,351.6 652.6 1.34 (1.29, 1.40) 1.21 (1.16, 1.26) 
 Periods on long-term opioids (ADD < 20mg MED) 3,318 50,985.4 650.8 1.32 (1.27, 1.38) 1.16 (1.11, 1.21) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 1,040 16,795.9 619.2 1.30 (1.21, 1.39) 1.31 (1.22, 1.40) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 364 4,570.3 796.4 1.68 (1.51, 1.87) 1.54 (1.39, 1.72) 
       
Incident iron deficiency anaemiac      
Periods not on long-term opioids 1,688 133,904.0 126.1 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 1,465 76,854.3 190.6 1.48 (1.38, 1.59) 1.37 (1.27, 1.47) 
 Periods on long-term opioids (ADD < 20mg MED) 966 54,009.5 178.9 1.38 (1.27, 1.50) 1.26 (1.16, 1.37) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 364 17,842.8 204.0 1.59 (1.42, 1.78) 1.54 (1.37, 1.73) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 135 5,002.0 269.9 2.11 (1.77, 2.52) 1.87 (1.57, 2.24) 
       
Incident gastrointestinal pathologyc      
Periods not on long-term opioids 1,368 135,393.1 101.0 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 1,098 77,473.1 141.7 1.33 (1.22, 1.44) 1.24 (1.14, 1.35) 
 Periods on long-term opioids (ADD < 20mg MED) 707 54,534.9 129.6 1.20 (1.09, 1.32) 1.12 (1.01, 1.23) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 286 17,885.8 159.9 1.52 (1.33, 1.72) 1.44 (1.27, 1.64) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 105 5,052.3 207.8 1.99 (1.63, 2.43) 1.77 (1.45, 2.17) 
       
Incident gastrointestinal bleedingc      
Periods not on long-term opioids 550 139,535.3 39.4 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 462 79,912.1 57.8 1.37 (1.20, 1.56) 1.24 (1.09, 1.41) 
 Periods on long-term opioids (ADD < 20mg MED) 307 56,012.5 54.8 1.28 (1.10, 1.48) 1.14 (0.99, 1.33) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 108 18,618.5 58.0 1.39 (1.13, 1.72) 1.33 (1.08, 1.64) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 47 5,281.2 89.0 2.17 (1.61, 2.93) 1.94 (1.43, 2.62) 
       
Incident addiction (non-opioids) c      
Periods not on long-term opioids 208 140,443.4 14.8 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 245 80,101.6 30.6 1.85 (1.53, 2.25) 1.82 (1.50, 2.21) 
 Periods on long-term opioids (ADD < 20mg MED) 119 56,356.1 21.1 1.23 (0.97, 1.56) 1.31 (1.03, 1.66) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 88 18,522.8 47.5 2.93 (2.27, 3.77) 2.49 (1.93, 3.21) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 38 5,222.6 72.8 4.57 (3.23, 6.46) 3.35 (2.36, 4.76) 
       
Incident addiction (opioids) c      
Periods not on long-term opioids 36 141,459.6 2.5 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 65 81,214.7 8.0 2.79 (1.83, 4.26) 3.07 (1.99, 4.72) 
 Periods on long-term opioids (ADD < 20mg MED) 17 56,882.0 3.0 0.96 (0.53, 1.74) 1.20 (0.66, 2.20) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 24 18,951.6 12.7 4.38 (2.60, 7.41) 3.73 (2.19, 6.33) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 24 5,381.0 44.6 15.87 (9.43, 26.72) 10.65 (6.27, 18.12) 
       
Accidental poisoningb      
Periods not on long-term opioids 26 141,627.5 1.8 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 44 81,333.2 5.4 2.93 (1.77, 4.83) 2.50 (1.51, 4.14) 
 Periods on long-term opioids (ADD < 20mg MED) 23 56,898.4 4.0 2.14 (1.20, 3.83) 1.88 (1.05, 3.38) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 13 18,993.8 6.8 3.64 (1.86, 7.13) 3.01 (1.53, 5.94) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 8 5,441.1 14.7 7.78 (3.51, 17.24) 5.84 (2.60, 3.11) 
       
Attempted suicide/self-harmb      
Periods not on long-term opioids 7 141,694.1 0.5 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 3 81,407.6 0.4 0.52 (0.13, 2.08) 0.51 (0.12, 2.13) 
 Periods on long-term opioids (ADD < 20mg MED) 1 56,927.6 0.2 0.23 (0.03, 1.94) 0.29 (0.03, 2.52) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 1 19,020.4 0.5 0.81 (0.10, 6.65) 0.67 (0.08, 5.62) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 1 5,459.6 1.8 2.96 (0.36, 24.3) 1.12 (0.11, 11.38) 
ADD, average daily dose; MED, morphine equivalent dose; aAdjusted for age, index year, geographical region, smoking and alcohol status, body mass index, deprivation, 
depression consultation, comorbidity, and co-prescribing of non-steroidal anti-inflammatory drug ; bAlso adjusted for prior occurrence of adverse event; cExcluded patients with 
previous record of event. 
 
 
Table 1. Morphine equivalent dose (MED) in mg, per 1 mg of opioid analgesic 
 
Opioid Analgesic (1mg) Morphine Equivalent Dose (mg)   
Non-controlled opioids 
 
  
Codeine 0.15 
Co-proxamol  0.23 
Dihydrocodeine 0.25 
Meptazinol 0.04 
Tramadol (Controlled since 06/2014) 0.1   
Controlled opioids 
 
  
Alfentanil Hydrochloride  30 
Buprenoprhine Sublingual Tablets 80 
Buprenorphine Transdermal Patches 75 
Dextromoramide/Palfium  3 
Diamorphine 3 
Dipipanone hydrochloride/Diconal 0.5 
Fentanyl mcg/hr patch (for 24 hours) 2.4 
Fentanyl Lozenge 130 
Fentanyl Nasal Spray 160 
Hydromorphone 4 
Levorphanol  6 
Morphine 1 
Methadone 3 
Oxycodone 1.5 
Papaveretum/Omnopon  0.75 
Pentazocine 0.12 
Pethidine 0.1 
Tapentadol  0.4 
 
 
 
Table 2 - Participant characteristics at baseline 
 
Participants, n 98,140 
Age at start of follow-up, median (IQR) 61 (47, 73) 
Male, n (%) 40,203 (41.0) 
Year of start of follow-up, median (IQR) 2007 (2005, 2009) 
Geographical region, n (%)  
 London  8,375 (8.5) 
 South 34,051 (34.7) 
 Midlands and East 27,457 (28.0) 
 North 28,257 (28.8) 
Smoking, n (%)  
 Non smoker 48,223 (49.1) 
 Ever smoker 37,634 (38.4) 
 Unknown 12,283 (12.5) 
Alcohol drinking, n (%)  
 Non drinker 12,643 (12.9) 
 Ever drinker 72,646 (74.0) 
 Unknown 12,851 (13.1) 
Body mass index, n (%)   
 < 25 kg/m2 26,748 (27.3) 
 ≥ 25 kg/m2 60,054 (61.2) 
 Unknown 11,338 (11.6) 
Neighbourhood Deprivation level, n (%)  
 1 (least) 17,882 (18.2) 
 2 21,398 (21.8) 
 3 19,067 (19.4) 
 4 19,612 (20.0) 
 5 (most) 19,582 (20.0) 
 Unknown 599 (0.6) 
Depression consultationa, n (%) 6,615 (6.7) 
Co-prescribing NSAIDb, n (%)  
 None 52,734 (53.7) 
 Basic oral NSAID only 38,698 (39.4) 
 COX-2 6,708 (6.8) 
Comorbidity (total number of prescriptions)a, 
median (IQR) 
9 (6, 14) 
a in 15 months prior to start of follow-up; b in 4 months prior to start of follow-up; IQR, 
interquartile range; NSAID, Non-steroidal anti-inflammatory drug; COX-2, selective 
cyclooxygenase-2 inhibitor 
 
 
Table 3 Average daily dose of prescribed opioids during the long-term opioid episodes 
Percentiles Average daily dose in morphine 
equivalents, all patients 
Average daily dose in 
morphine equivalents, males 
Average daily dose in morphine 
equivalents, females 
5% 3.1 mg 3.3 mg 3.0 mg 
25% 7.1 mg 7.7 mg 6.7 mg 
50% (median) 12.3 mg 13.2 mg 11.7 mg 
75% 20.3 mg 21.4 mg 19.5 mg 
95% 42.8 mg 44.0 mg 42.0 mg 
 
Table 4 - Risks of major trauma and overdose in musculoskeletal patients newly prescribed long-term opioids 
Adverse event Number of 
events 
Time at risk 
(person-years) 
Absolute risk 
(per 10,000 person-
years) 
Crude hazard ratio 
(95% CI) 
Adjusteda hazard ratio 
(95% CI) 
Major trauma      
Periods not on long-term opioids 6,454 226,140.4 285.4 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 4,587 122,105.1 375.7 1.22 (1.17, 1.27) 1.14 (1.10, 1.19) 
 Periods on long-term opioids (daily MED < 20mg) 3,150 85,323.3 369.2 1.18 (1.13, 1.23) 1.09 (1.04, 1.14) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 1,096 28,729.5 381.5 1.26 (1.18, 1.35) 1.24 (1.16, 1.32) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 341 8,052.2 423.5 1.42 (1.27, 1.58) 1.34 (1.20, 1.50) 
       
Overdose (non-opioids)      
Periods not on long-term opioids 478 243,956.2 19.6 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 407 129,870.4 31.3 1.32 (1.15, 1.52) 1.23 (1.07, 1.42) 
 Periods on long-term opioids (ADD < 20mg MED) 189 90,388.6 20.9 0.84 (0.71, 1.01) 0.91 (0.77, 1.09) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 158 30,753.0 51.4 2.25 (1.88, 2.71) 1.71 (1.42, 2.06) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 60 8,728.8 68.7 3.13 (2.39, 4.10) 1.71 (1.30, 2.25) 
       
Overdose (opioids)      
Periods not on long-term opioids 118 245,001.3 4.8 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 151 130,386.5 11.6 2.16 (1.68, 2.78) 2.24 (1.73, 2.89) 
 Periods on long-term opioids (ADD < 20mg MED) 67 90,609.7 7.4 1.31 (0.96, 1.79) 1.59 (1.16, 2.19) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 56 30,952.7 18.1 3.41 (2.47, 4.71) 2.83 (2.04, 3.92) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 28 8,824.1 31.7 6.15 (4.06, 9.30) 3.81 (2.50, 5.80) 
ADD, average daily dose; MED, morphine equivalent dose; a Adjusted for  age, gender, index year, geographical region, smoking and alcohol status, body mass index, 
deprivation, depression consultation, comorbidity, co-prescribing of non-steroidal anti-inflammatory drug, and for prior occurrence of adverse event. 
 
 
Table 5 - Risks of falls, iron deficiency anaemia, gastrointestinal pathology, addiction, accidental poisoning and attempted 
suicide/self-harm in musculoskeletal patients newly prescribed long-term opioids 
Adverse event Number of events Time at risk 
(person-years) 
Absolute risk 
(per 10,000 person-
years) 
Crude hazard ratio 
(95% CI) 
Adjusteda hazard ratio 
(95% CI) 
Fallsb      
Periods not on long-term opioids 8,186 221,533.7 369.5 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 6,507 118,554.4 548.9 1.39 (1.35, 1.44) 1.23 (1.19, 1.28) 
 Periods on long-term opioids (ADD < 20mg MED) 4,534 82,868.0 547.1 1.38 (1.33, 1.43) 1.17 (1.12, 1.21) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 1,461 28,002.6 521.7 1.35 (1.28, 1.43) 1.34 (1.27, 1.42) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 512 7,683.8 666.3 1.74 (1.59, 1.90) 1.64 (1.50, 1.80) 
       
Incident iron deficiency anaemiac      
Periods not on long-term opioids 2,501 234,507.3 106.6 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 2,085 124,349.5 167.7 1.55 (1.46, 1.65) 1.38 (1.29, 1.46) 
 Periods on long-term opioids (ADD < 20mg MED) 1,356 86,696.0 156.4 1.44 (1.34, 1.54) 1.24 (1.16, 1.33) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 535 29,389.9 182.0 1.69 (1.53, 1.85) 1.61 (1.46, 1.77) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 194 8,263.6 234.8 2.18 (1.89, 2.53) 1.97 (1.70, 2.28) 
       
Incident gastrointestinal pathologyc      
Periods not on long-term opioids 2,419 234,393.5 103.2 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 1,812 124,218.2 145.9 1.35 (1.27, 1.44) 1.25 (1.17, 1.33) 
 Periods on long-term opioids (ADD < 20mg MED) 1,176 86,813.8 135.5 1.24 (1.15, 1.33) 1.14 (1.06, 1.22) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 454 29,209.8 155.4 1.45 (1.31, 1.61) 1.37 (1.24, 1.52) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 182 8,194.6 222.1 2.10 (1.80, 2.44) 1.90 (1.63, 2.21) 
       
Incident gastrointestinal bleedingc      
Periods not on long-term opioids 1,039 241,217.7 43.1 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 774 128,056.4 60.4 1.31 (1.18, 1.44) 1.18 (1.07, 1.31) 
 Periods on long-term opioids (ADD < 20mg MED) 509 89,095.8 57.1 1.22 (1.09, 1.36) 1.09 (0.97, 1.22) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 185 30,360.1 60.9 1.34 (1.14, 1.57) 1.26 (1.08, 1.48) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 80 8,600.5 93.0 2.07 (1.65, 2.60) 1.88 (1.49, 2.37) 
       
Incident addiction (non-opioids) c      
Periods not on long-term opioids 561 242,278.0 23.2 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 562 128,106.6 43.9 1.69 (1.50, 1.91) 1.68 (1.49, 1.91) 
 Periods on long-term opioids (ADD < 20mg MED) 280 89,548.5 31.3 1.16 (1.0, 1.35) 1.25 (1.08, 1.46) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 198 30,141.4 65.7 2.58 (2.19, 3.04) 2.22 (1.88, 2.62) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 84 8,416.7 99.8 4.01 (3.18, 5.05) 2.99 (2.37, 3.78) 
       
Incident addiction (opioids) c      
Periods not on long-term opioids 90 244,623.9 3.7 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 142 130,193.0 10.9 2.51 (1.90, 3.30) 2.83 (2.13, 3.76) 
 Periods on long-term opioids (ADD < 20mg MED) 35 90,580.3 3.9 0.81 (0.54, 1.21) 1.06 (0.71, 1.60) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 56 30,915.9 18.1 4.17 (2.97, 5.86) 3.59 (2.55, 5.06) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 51 8,696.8 58.6 14.05 (9.93, 19.88) 9.33 (6.55, 13.29) 
       
Accidental poisoningb      
Periods not on long-term opioids 47 245,249.7 1.9 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 61 130,558.2 4.7 2.47 (1.66, 3.68) 2.09 (1.40, 3.12) 
 Periods on long-term opioids (ADD < 20mg MED) 31 90,650.3 3.4 1.77 (1.10, 2.84) 1.53 (0.95, 2.47) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 19 31,038.7 6.1 3.17 (1.85, 5.43) 2.64 (1.53, 4.56) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 11 8,869.3 12.4 6.43 (3.32, 12.42) 4.76 (2.43, 9.32) 
       
Attempted suicide/self-harmb      
Periods not on long-term opioids 14 245,360.7 0.6 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 9 130,649.6 0.7 1.05 (0.44, 2.49) 1.01 (0.42, 2.45) 
 Periods on long-term opioids (ADD < 20mg MED) 4 90,686.5 0.4 0.65 (0.21, 2.02) 0.74 (0.23, 2.35) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 3 31,071.6 1.0 1.52 (0.43, 5.35) 1.24 (0.35, 4.40) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 2 8,891.5 2.2 3.63 (0.82, 16.05) 1.87 (0.40, 8.74) 
ADD, average daily dose; MED, morphine equivalent dose; aAdjusted for age, gender, index year, geographical region, smoking and alcohol status, body mass index, 
deprivation, depression consultation, comorbidity, and co-prescribing of non-steroidal anti-inflammatory drug ; bAlso adjusted for prior occurrence of adverse event; cExcluded 
patients with previous record of event. 
 
 
 
Table 6 - Risks of eczema and psoriasis in musculoskeletal patients newly prescribed long-term opioids 
Adverse event Number of events Time at risk 
(person-years) 
Absolute risk 
(per 10,000 person-
years) 
Crude hazard ratio 
(95% CI) 
Adjusteda hazard ratio 
(95% CI) 
Incident eczemab      
Periods not on long-term opioids 2,443 232,337.7 105.1 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 1,522 124,982.2 121.8 1.11 (1.04, 1.18) 1.07 (0.99, 1.13) 
 Periods on long-term opioids (ADD < 20mg MED) 1,025 87,031.0 117.8 1.06 (0.98, 1.15) 1.04 (0.97, 1.13) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 383 29,534.1 129.7 1.19 (1.07, 1.33) 1.13 (1.00, 1.26) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 114 8,417.1 135.4 1.26 (1.04, 1.52) 1.10 (0.91, 1.33) 
       
Incident psoriasisb      
Periods not on long-term opioids 919 239,887.8 38.3 1.0 (referent) 1.0 (referent) 
Periods on long-term opioids (combined) 559 127,960.4 43.7 1.02 (0.92, 1.14) 0.98 (0.88, 1.10) 
 Periods on long-term opioids (ADD < 20mg MED) 389 88,855.5 43.8 1.01 (0.89, 1.14) 1.0 (0.88, 1.13) 
 Periods on long-term opioids (20 ≤ ADD < 50mg MED) 130 30,461.4 42.7 1.03 (0.86, 1.24) 0.94 (0.78, 1.12) 
 Periods on long-term opioids (ADD ≥ 50mg MED) 40 8,643.5 46.3 1.14 (0.83, 1.56) 0.96 (0.70, 1.32) 
ADD, average daily dose; MED, morphine equivalent dose; aAdjusted for age, gender, index year, geographical region, smoking and alcohol status, body mass index, 
deprivation, depression consultation, comorbidity, and co-prescribing of non-steroidal anti-inflammatory drug; bExcluded patients with previous record of event 
